Related Experiment Video
Updated: Jul 12, 2025
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.0K
Concurrent Atopic Dermatitis and Psoriasis Successfully Treated With Dual Biologic Therapy
Margaret A Kaszycki1, Jessica N Pixley1, Steven R Feldman1
1Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina.Dr. Feldman also is from the Department of Pathology and the Department of Social Sciences and Health Policy.
Cutis
|October 30, 2023
Summary
Concurrent atopic dermatitis (AD) and psoriasis can be challenging to diagnose and treat. Dual biologic therapy with dupilumab and guselkumab offers a successful treatment option for patients with treatment-resistant, coexisting skin conditions.
Area of Science:
- Dermatology
- Immunopathology
Background:
- Atopic dermatitis (AD) and psoriasis are chronic inflammatory skin diseases with overlapping clinical and histopathological features.
- These overlapping features can complicate diagnosis and treatment, suggesting an underlying immunopathological spectrum.
- Coexistence of AD and psoriasis is rare but presents significant management challenges.
Observation:
- A case report details a patient with long-standing, treatment-resistant AD and psoriasis.
- The patient experienced successful treatment using dual biologic therapy.
- Diagnostic modalities including patch testing and tissue biopsy were utilized.
Findings:
- Dual biologic therapy with dupilumab and guselkumab demonstrated efficacy in a patient with concurrent, treatment-resistant AD and psoriasis.
- Comprehensive patient assessment, including diagnostic testing, is crucial for managing overlapping skin conditions.
- Clinical response alongside diagnostic data aids in treatment decision-making.
Implications:
- This case highlights the importance of considering coexisting AD and psoriasis in refractory cases.
- Dual biologic therapy is a viable therapeutic strategy for managing patients with both conditions.
- Further research into the immunopathological overlap and optimal treatment strategies for concurrent AD and psoriasis is warranted.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
148
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
148
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
170
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
170
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
122
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
122
01:29Inflammatory Bowel Disease IV: Pharmacological Management
134
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
134
01:28Drug Therapy
47
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
47
01:29Drugs for Treatment of Ulcerative Colitis in IBD
149
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
149